Inactive Instrument

WuXi Biologics (Cayman) Inc. Share Price Hong Kong S.E.

Equities

2269

KYG970081090

Biotechnology & Medical Research

Financials

Sales 2024 * 18.18B 2.51B 19.61B 210B Sales 2025 * 21.76B 3B 23.47B 251B Capitalization 53.84B 7.44B 58.07B 620B
Net income 2024 * 3.89B 538M 4.2B 44.85B Net income 2025 * 4.93B 680M 5.31B 56.77B EV / Sales 2024 * 2.57 x
Net cash position 2024 * 7.11B 982M 7.67B 81.95B Net cash position 2025 * 8.06B 1.11B 8.7B 92.93B EV / Sales 2025 * 2.1 x
P/E ratio 2024 *
14.3 x
P/E ratio 2025 *
11.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.47%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 52 01/11/01
Director of Finance/CFO 54 23/21/23
Chief Tech/Sci/R&D Officer 57 -
Members of the board TitleAgeSince
Director/Board Member 73 06/23/06
Director/Board Member 75 17/17/17
Chairman 56 01/10/01
More insiders
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Related indices
More about the company